Search results
25 lis 2023 · All adult patients who had confirmed diagnosis of pemphigus vulgaris or pemphigus foliaceus, experienced treatment with rituximab (RTX) and were finally subjected to a combination therapy with mycophenolate mofetil, dapsone, or methotrexate due to:
In patients with moderate-to-severe PV, rituximab plus short-term prednisone was more effective than prednisone alone. Patients treated with rituximab had less CS exposure and were less likely to experience severe or life-threatening CS-related AEs.
23 lis 2020 · In the 2020 guidelines, injections of the anti-CD20 monoclonal antibody rituximab were included as a first-line therapy for moderate-to-severe pemphigus and/or for patients without disease control despite treatment with systemic glucocorticoids (GC) and immunosuppressive agents [4].
26 paź 2006 · Anti-CD20 chimeric monoclonal antibody (rituximab) for the treatment of recalcitrant, life-threatening pemphigus vulgaris with implications in the pathogenesis of the disorder. J Am Acad...
28 lis 2019 · There is evidence that the anti‐CD20 antibody rituximab is effective in the treatment of patients with severe recalcitrant pemphigus and in patients with newly diagnosed pemphigus. What does this study add?
Rituximab is currently in development for the treatment of pemphigus vulgaris when other treatments, including systemic steroids and steroid sparing agents have failed to control the disease. In the phase III clinical trial (NCT02383589), rituximab was administered at a dose of 1000 milligrams
7 lis 2022 · Anti-CD20 monoclonal antibody rituximab is an approved adjuvant treatment, in combination with oral corticosteroids, for patients with pemphigus vulgaris, a severe and potentially life-threatening autoimmune blistering skin disorder.
